Limited Competition: High Impact Specialized Innovation Programs in Clinical and Translational Science

The Limited Competition High Impact Specialized Innovation Programs in Clinical and Translational Science opportunity is administered by the National Institutes of Health within the U.S. Department of Health and Human Services, specifically through the National Center for Advancing Translational Sciences. This funding opportunity is part of the broader Clinical and Translational Science Award Program, which is congressionally mandated to accelerate the process of translating scientific discoveries into practical applications that improve patient care and public health outcomes. The program supports a nationwide network of academic medical centers and research institutions that work collaboratively to move innovations from laboratory research into clinical practice and community health settings. The purpose of this specialized innovation program is to support the development and demonstration of unique capabilities, research platforms, and resources at institutions that are already funded under the Clinical and Translational Science Award Program. These Specialized Innovation Programs are designed to address critical gaps, barriers, or inefficiencies in the translational science ecosystem. By targeting high impact needs, the program aims to enhance infrastructure, introduce novel approaches, and strengthen the overall effectiveness of translational research activities within funded hubs. Funding is expected to support projects that create or expand innovative tools, systems, or collaborative frameworks that improve the speed and quality of translational research. While specific allowable costs are not detailed in the forecast, typical NIH grants support personnel, research infrastructure, data systems, and collaborative initiatives that align with program objectives. There is no cost sharing or matching requirement associated with this opportunity, which lowers the financial burden on applicant institutions and allows them to focus resources on programmatic development and implementation. Eligibility for this opportunity is highly restricted. Only institutions that have successfully competed for and received funding under the Clinical and Translational Science Award Program UM1 funding opportunity announcement PAR-24-272 or its subsequent iterations are eligible to apply. This makes the opportunity a limited competition, meaning that only a predefined group of existing awardees can submit applications. These institutions are typically large academic medical centers or research universities with established translational science infrastructure and demonstrated capacity for innovation. The application process is expected to follow standard NIH submission procedures. Although the opportunity is currently in forecast status, eligible institutions will be invited to submit applications once the official notice of funding opportunity is released. Applications will undergo NIH peer review, where they will be evaluated for scientific merit, innovation, feasibility, and alignment with program goals. Only applications deemed meritorious through this rigorous review process will be considered for funding. The timeline for this opportunity indicates that the estimated posting date is September 1, 2026, with an anticipated application due date of January 25, 2027. Awards are expected to be issued around December 15, 2027, with the project start date aligned to the same timeframe. As a forecasted opportunity, these dates are subject to change, and applicants should monitor official NIH communications for updates. The program operates within the federal fiscal year 2028 cycle, and future iterations may follow a recurring pattern tied to CTSA program cycles. For additional information or inquiries, applicants are directed to contact the Division of Clinical Innovation within the National Center for Advancing Translational Sciences via email. This centralized contact ensures that applicants receive consistent guidance regarding eligibility, application requirements, and program expectations. Overall, this funding opportunity represents a targeted investment in advancing translational science capabilities among already established research hubs, with the goal of accelerating impactful health innovations nationwide.